Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "RNA Interference Therapy-Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The "RNA Interference Therapy - Competitive ...

Three Vietnamese researchers in Hong Kong have solved a 20-year puzzle in molecular biology that could reshape how scientists develop cancer treatments based on RNA interference.

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will focus ...

An RNA interference therapy, targeting ANGPTL3 in the liver, drastically reduced fasting triglycerides in people with mixed hyperlipidemia, the ARCHES-2 trial showed. Used atop usual statins and other ...

The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial. In such individuals, known to be at ...

Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months ...

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly ...

(MENAFN- GlobeNewsWire - Nasdaq) RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing ...